You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies
  1. Kevin G Blyth1,2
  1. 1Department of Respiratory Medicine, Southern General Hospital, Glasgow, UK
  2. 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK
  1. Correspondence to Dr Kevin G Blyth, Department of Respiratory Medicine, Long-Term Ventilation Unit, Southern General Hospital, 1345 Govan Road, Glasgow G51 4TF, UK; kevin.blyth{at}ggc.scot.nhs.uk

https://doi.org/10.1136/thoraxjnl-2014-206464

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Reproducibility is a quality that all biomarkers must demonstrate before entering the clinical arena. In October's issue of Thorax, Creaney et al1 reported important diagnostic performance data regarding fibulin-3 in malignant pleural mesothelioma (MPM). Their results (plasma area under the curve (AUC) 0.671, sensitivity 21%) are remarkably discordant with those reported by Pass et al,2 using the same assay in a similarly designed study (plasma AUC 0.974–0.997, sensitivity 97%). Although some discordance is expected, this pattern is common in the MPM biomarker …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles